ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States.
about
KASL clinical practice guidelines: management of hepatitis CDiagnosis, management, and treatment of hepatitis C: an updateDifferences in heart rate variability parameters during the post-dialytic period in type II diabetic and non-diabetic ESRD patients.Hepatitis C virus infection and dialysis: 2012 update.[Profile of diabetic in chronic hemodialysis: a multicenter study in Morocco]The EVEREST study: an international collaboration.Vascular disease, ESRD, and death: interpreting competing risk analyses.Exploring the association between macroeconomic indicators and dialysis mortality.Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials.Survival analysis of Korean end-stage renal disease patients according to renal replacement therapy in a single center[Profile of chronic renal failure in diabetes at initiation of hemodialysis in the nephrology and dialysis service of the military hospital in Rabat, Morocco].A prospective study: inflammation, infection and comorbidity in patients on long-term dialysis.Dialysis in The Netherlands: the clinical condition of new patients put into a European perspective. NECOSAD Study Group. Netherlands Cooperative Study on the Adequacy of Dialysis phase 1.Trends in Renal Replacement Therapy in Bosnia and Herzegovina 2002-2008.Decreased percentage of peripheral naïve T cells is independently associated with ischemic stroke in patients on hemodialysis.Hepatitis status and mortality in hemodialysis population.KASL clinical practice guidelines: management of hepatitis C.Survival in patients on hemodialysis: Effect of gender according to body mass index and creatinine.
P2860
Q26752471-0E4DDDFF-18D5-4F9F-A759-E8076C71A263Q29619682-BB5F2376-E92F-4FF2-9F07-F76FB3F38E74Q32135820-E771AB9D-2A20-40F0-9C7B-B7BC7F28985FQ33710828-86574506-27DC-48E7-862A-B67613F6AE25Q34444873-3CEAD650-E537-4144-AD38-70FB6E92E1D0Q35574292-3A50E994-54AF-45EA-94E4-B0FF2307EE06Q36294356-32DF8287-C2A5-4C38-9B7E-18D865DF256DQ36294385-E8453900-11EF-44DD-9A74-012D795DEC03Q37053900-2C7ED648-A801-42A0-ABF9-13171677C939Q37220288-24F8D81A-FD33-477A-85F5-019D7A2B87C8Q37314981-3616F5E2-8F57-4EC5-8A87-ACC696CBB802Q37845374-7BBFDAB8-60F6-45C8-85C5-6026278A94E7Q40793173-961B7D8A-BDB1-43EB-AC37-D0032BE330DFQ42273807-E7646F1C-CB0A-49EA-9A72-C09F3B0753D3Q50060242-411CC20F-4D3F-4E88-B442-505530975AFAQ51662874-AD7B3D36-01CD-44DE-9B23-E55DE6CA1B88Q51836024-535F687F-1848-41A0-83E7-E4F3BEB67C32Q55111034-A5CAB01A-A241-470A-B96C-9A45A2C93D78
P2860
ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
ESRD patient mortality with ad ...... aly) versus the United States.
@en
ESRD patient mortality with adjustment for comorbid conditions in Lombardy
@nl
type
label
ESRD patient mortality with ad ...... aly) versus the United States.
@en
ESRD patient mortality with adjustment for comorbid conditions in Lombardy
@nl
prefLabel
ESRD patient mortality with ad ...... aly) versus the United States.
@en
ESRD patient mortality with adjustment for comorbid conditions in Lombardy
@nl
P2093
P921
P356
P1433
P1476
ESRD patient mortality with ad ...... aly) versus the United States.
@en
P2093
P2888
P304
P356
10.1038/KI.1996.403
P407
P577
1996-09-01T00:00:00Z
P5875
P6179
1015102984